Abstract: The invention relates to the field of binding molecules comprising at least one single variable antibody domain, targeted at receptors present on fibrogenic effector cells, such as activated hepatic stellate cells in liver fibrosis, activated interstitial fibroblasts or vascular smooth muscle cells in lung fibrosis, activated mesangial- or interstitial fibroblasts in renal fibrosis, activated dermal fibroblasts in systemic sclerosis/scleroderma, activated fibroblasts in inflammatory bowel disease, or tumor-supporting stromal fibroblasts in sclerosing malignant tumors. More in particular, the invention relates to internalizing binding molecules for cell-specific targeted delivery of anti-fibrotic substances. The invention also relates to a binding molecule comprising at least two single variable antibody domains, each targeting a receptor on said fibrogenic effector cells.

Abstract: The invention relates to the field of binding molecules comprising at least one single variable antibody domain, targeted at receptors present on myofibroblasts and/or hepatic stellate cells (HSCs). The invention also relates to a binding molecule comprising at least two single variable antibody domains, each targeting a receptor on HSCs and/or on myofibroblasts. The invention further relates to nucleic acids encoding such binding molecules, a host cell for expression of such binding molecules and to methods for preparing such binding molecules. The invention further relates to pharmaceutical compositions that comprise such binding molecule and to uses of such binding molecules and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.